This is a ready-to-use, criteria-scored risk assessment for selecting a container closure integrity test (CCIT) method among two or more candidates. Replace every <<FILL: ...>> placeholder with your own specifics, run the scoring with a cross-functional team, and route it through your normal document control, review, and approval. A worked filled specimen follows the template. Verify each cited reference against the current source before you rely on it. This content is educational and general, not regulatory advice; adapt and verify it for your product and commitments.
Document control header
| Field | Entry |
|---|---|
| Assessment title | CCIT Method Selection, <<FILL: product / package>> |
| Document number | <<FILL: RA-ID>> |
| Version / date | <<FILL>> |
| Feeds | <<FILL: MALL derivation worksheet ID; CCIT method validation protocol ID>> |
| QRM method | Criteria-scored comparative selection, adapted for CCIT method fit |
| Team (cross-functional) | <<FILL: Container Closure SME, Validation/Engineering, Microbiology, QA, Manufacturing>> |
1. Purpose
This assessment compares candidate CCIT methods against a fixed set of scored criteria for <<FILL: product / package>>, and documents a defensible method choice with its rationale, rather than a method chosen by habit, vendor availability, or precedent alone. USP <1207> expects a documented method selection rationale; this is that document.
2. Scope
This assessment covers method selection for <<FILL: container format, e.g. 10 mL glass vial / prefilled syringe / flexible bag>> filled with <<FILL: liquid / lyophilized / suspension product>>. It takes the governing maximum allowable leakage limit (MALL) and the required detection limit as inputs from <<FILL: MALL derivation worksheet ID>>, and it does not re-derive the MALL. It does not constitute method validation, which is a separate protocol, <<FILL: validation protocol ID>>, executed once this assessment selects a method.
3. Responsibilities
| Role | Responsibility |
|---|---|
| Container closure / packaging SME | Leads the assessment, proposes candidate methods, confirms package-format fit. |
| Validation / engineering | Provides method capability data, scores technical fit, plans the validation that follows. |
| Microbiology | Confirms the sterility-driven sensitivity requirement is addressed by the selected strategy. |
| Manufacturing | Scores throughput and operational fit against line speed and staffing. |
| Quality Assurance | Reviews scoring, approves the selection, and confirms the rationale is inspection-ready. |
4. Inputs to this assessment
| Input | Value | Source |
|---|---|---|
| Governing MALL | <<FILL>> | <<FILL: MALL worksheet ID>> |
| Required method detection limit (with margin) | <<FILL>> | <<FILL: MALL worksheet ID>> |
| Critical attributes protected | <<FILL: sterility; O2; moisture; other>> | <<FILL>> |
| Package format | <<FILL: vial; syringe; cartridge; flexible bag; BFS; other>> | <<FILL>> |
| Product conductivity / optical properties | <<FILL>> | <<FILL>> |
| Required test mode | <<FILL: 100 percent in-line / sampled off-line / stability time point>> | <<FILL>> |
| Target throughput | <<FILL: units per hour, or sample turnaround time>> | <<FILL>> |
5. Candidate methods under consideration
List two to four realistic candidates. Do not score every method in the field; score the ones that plausibly fit this package and product.
| Candidate | Class (deterministic/probabilistic) | Brief description |
|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> |
6. Scoring methodology and scales
Score each candidate against each criterion on a 1 to 3 scale, 3 being the strongest fit. Multiply each criterion score by its weight and sum for a total. State the weights before scoring, not after seeing the totals.
Sensitivity fit (against the required detection limit from section 4):
| Score | Meaning |
|---|---|
| 3 | Demonstrated or well-precedented detection with clear margin below the required limit, no method development needed |
| 2 | Plausible fit but requires method development or a tighter validation study to confirm margin |
| 1 | Insufficient without a fundamentally different approach, or only reaches the limit with no margin |
Package and product fit (format, fill type, headspace, conductivity or optical properties):
| Score | Meaning |
|---|---|
| 3 | Established, precedented use on this exact format and fill type |
| 2 | Used on similar formats, needs fixturing or recipe development for this specific package |
| 1 | Poor fit (for example HVLD on a very low-conductivity fill, or headspace analysis on opaque flexible film) |
Destructive/non-destructive impact:
| Score | Meaning |
|---|---|
| 3 | Non-destructive, supports 100 percent in-line or stability reuse where relevant |
| 2 | Non-destructive but with a throughput or fixturing cost |
| 1 | Destructive, consumes the tested unit |
Throughput and operational fit (against section 4 target):
| Score | Meaning |
|---|---|
| 3 | Meets or exceeds the required throughput at the required test mode |
| 2 | Meets throughput for sampled/off-line use but not for 100 percent in-line, or vice versa |
| 1 | Well below the required throughput for the intended test mode |
Validation and regulatory posture:
| Score | Meaning |
|---|---|
| 3 | Deterministic, well precedented, straightforward to defend against USP <1207>‘s stated preference |
| 2 | Deterministic but less common for this format, needs a stronger validation narrative |
| 1 | Probabilistic, or deterministic with an unusual justification burden |
7. Scoring table
| Criterion | Weight | <<FILL: Candidate A>> score | Weighted | <<FILL: Candidate B>> score | Weighted | <<FILL: Candidate C>> score | Weighted |
|---|---|---|---|---|---|---|---|
| Sensitivity fit | <<FILL: e.g. 3>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Package/product fit | <<FILL: e.g. 3>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Destructive/non-destructive | <<FILL: e.g. 2>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Throughput/operational fit | <<FILL: e.g. 2>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Validation/regulatory posture | <<FILL: e.g. 1>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Total | <<FILL>> | <<FILL>> | <<FILL>> |
8. Selection outcome and rationale
State the selected method, its total score relative to the other candidates, and the qualitative reasons a reader would need even without the scoring table: <<FILL>>.
Where the highest-scoring candidate does not fully satisfy every criterion (for example, a sub-micron sterility MALL that no routine deterministic method reaches directly), state the complementary strategy here, for example anchoring that limit through a helium tracer correlation performed once during method development while the routine method is validated against a looser, attribute-driven limit with margin: <<FILL>>.
9. Gaps and mitigations for the selected method
| Gap | Mitigation | Owner |
|---|---|---|
<<FILL: e.g. HVLD alone does not directly demonstrate the sub-micron sterility MALL>> | <<FILL: e.g. anchor via helium tracer correlation during method development; document in the validation protocol>> | <<FILL>> |
<<FILL: e.g. product conductivity marginal for reliable HVLD signal>> | <<FILL: e.g. confirm detectability in early method development before committing to full validation>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> |
10. Residual risk statement
State the residual risk after mitigation, in plain terms: what remains unaddressed by the selected method and mitigation plan, and why it is acceptable to proceed to validation. <<FILL>>.
11. Approval
| Role | Name | Signature | Date |
|---|---|---|---|
| Author | <<FILL>> | ||
| Container Closure SME | <<FILL>> | ||
| Microbiology | <<FILL>> | ||
| Quality Assurance | <<FILL>> |
12. References
USP General Chapter <1207> Package Integrity Evaluation, Sterile Products (and <1207.1>, <1207.2>). EU GMP Annex 1, Manufacture of Sterile Medicinal Products (2022). ICH Q9, Quality Risk Management.
Confirm the current version and clause numbers of each reference before issue. USP and ICH documents are copyrighted; cite by number and title and describe them in your own words rather than pasting their text.
13. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL: date>> | <<FILL: author>> | Initial issue. |
Filled specimen
The following shows the assessment completed for an example 10 mL liquid-filled vial of a conductive, oxygen-sensitive sterile biologic with a nitrogen overlay, comparing HVLD, vacuum decay, and headspace gas analysis. The same product example appears in the parent article’s worked validation example, so the numbers connect. Illustrative only; replace with your own.
Inputs: governing MALL for the routine method is approximately 5 microns (oxygen-driven; the sub-micron sterility MALL is handled through helium correlation, not the routine method); package is a 10 mL Type I glass vial, liquid fill, conductive formulation, nitrogen overlay; required test mode is 100 percent in-line at commercial line speed.
Scoring table (weights: sensitivity 3, package/product fit 3, destructive/non-destructive 2, throughput 2, validation posture 1):
| Criterion | Weight | HVLD score | Weighted | Vacuum decay score | Weighted | Headspace analysis score | Weighted |
|---|---|---|---|---|---|---|---|
| Sensitivity fit | 3 | 3 | 9 | 2 | 6 | 1 | 3 |
| Package/product fit | 3 | 3 | 9 | 3 | 9 | 2 | 6 |
| Destructive/non-destructive | 2 | 3 | 6 | 3 | 6 | 3 | 6 |
| Throughput/operational fit | 2 | 3 | 6 | 2 | 4 | 1 | 2 |
| Validation/regulatory posture | 1 | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 33 | 28 | 20 |
Selection outcome: HVLD selected as the routine 100 percent in-line method. It scores highest on sensitivity fit and package/product fit for this conductive liquid-filled vial, and comfortably meets the throughput target. Vacuum decay is documented as the fallback if a future formulation change reduces conductivity below the level HVLD needs. Headspace gas analysis is not selected as the routine release method (lower throughput, does not directly probe the seal) but is added as a complementary stability-time-point test for the oxygen attribute, consistent with the parent article’s discussion of pairing a seal-probing method with headspace trending.
Gaps and mitigations: HVLD does not directly demonstrate the sub-micron sterility MALL; mitigated by anchoring that limit through a helium tracer correlation study performed once during method development and referenced in the validation protocol. High-voltage exposure risk to the protein is mitigated by product-compatibility testing (assay, sub-visible particles, oxidation markers) built into the validation protocol as a dedicated test case.
Residual risk: accepted. The sterility-driven limit is covered by the helium correlation rather than the routine curve, which is the standard, documented approach for a limit tighter than routine deterministic methods can resolve directly; this is stated explicitly rather than left implicit.
Common inspection findings this risk assessment prevents
- A method chosen with no documented comparison to alternatives, defended only as “what we always use.”
- Sensitivity, package fit, and throughput judged informally with no scored, reviewable rationale.
- A method’s known gap (for example, not directly reaching a sub-micron sterility limit) left unstated rather than documented with an explicit mitigation.
- Scoring weights chosen after seeing which method “should” win, rather than fixed in advance.
How to adapt this risk assessment
- Set your document number, product, and package in the header.
- Pull the governing MALL and detection requirement from your completed MALL derivation worksheet (section 4); do not re-derive them here.
- Limit candidates to two to four realistic options (section 5); do not score the entire method family for completeness’s sake.
- Set your weights (section 6/7) before scoring, and keep them consistent across products so results are comparable.
- Always complete section 9 (gaps and mitigations) even for the winning method; a method with no stated gap reads as unreviewed, not as flawless.